- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03556228
Selectieve TrkA-remmer VMD-928 voor de behandeling van door TrkA-overexpressie aangedreven solide tumoren of lymfoom
Een open-label onderzoek met meerdere doses en dosisescalatie om de veiligheid, farmacokinetiek en farmacodynamiek van VMD-928 te onderzoeken bij proefpersonen met solide tumoren of lymfoom
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Studie Overzicht
Toestand
Conditie
- Adenoïd cystisch carcinoom
- Alvleesklierkanker
- Slokdarmkanker
- Niet-kleincellige longkanker
- Longkanker
- Mesothelioom
- Hoofd-hals plaveiselcelcarcinoom
- Hoofd-halscarcinoom
- Hoofd- en nekkanker
- Hoofd-hals plaveiselcelcarcinoom HNSCC
- Hoofd- en nekkanker - Amandelen
- Speekselkliercarcinomen
- Kleincellige longkanker (SCLC)
- Hoofd- en nekkanker - Keel
- Hoofd- en nekkanker Lip
- Hoofd- en nekkanker Mondholte
- Hoofd-halskanker Nasopharynx
- Hoofd-halskanker Oropharynx
- Hoofd-halskanker Hypofarynx
- Hoofd- en nekkanker Strottenhoofd
- Hoofd- en nekkanker Luchtpijp
- Hoofd- en nekkanker - Speekselklier
- Hoofd- en nekkanker - Nasofaryngeaal
- Alle solide tumoren vorderden na een eerdere immunotherapie
- Longkanker (Lokaal Gevorderd of Uitgezaaid)
Interventie / Behandeling
Gedetailleerde beschrijving
This is an open-label, dose-escalation (Phase 1) and expansion (Phase 2) multi-center study conducted in five parts to identify the safe and pharmacologically active doses (MTD and/orRP2D) and regimen for oral VMD-928 monotherapy and in combination with a PD-1 inhibitor, pembrolizumab in cancer patients. An immunohistochemistry (IHC) assay specific for detecting TrkA protein in tumor tissue samples has been validated and is being used to detect TrkA protein expressions in patient tumor tissue samples at Pre-screening. The study is currently focusing on the top 5 solid tumor with the highest TrkA protein overexpression are: Head and Neck Cancers (HNC), Esophageal cancer, Lung cancers, Mesothelioma, and Pancreatic Cancer.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Jay Wu, PhD
- Telefoonnummer: 101 1-510-270-2790
- E-mail: OM@VMOncology.com
Studie Locaties
-
-
-
San Juan, Puerto Rico, 00935
- Werving
- PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200)
-
Contact:
- Karina M Rodriguez
- Telefoonnummer: (787) 407-3333
- E-mail: karina.rodriguez@panoncologytrials.com
-
Contact:
- Mariangelie López
- Telefoonnummer: (787) 407-3333
- E-mail: mariangelie.lopez@panoncologytrials.com
-
Hoofdonderzoeker:
- Marcia Cruz-Correa, MD, PhD
-
-
-
-
California
-
Santa Rosa, California, Verenigde Staten, 95403
- Werving
- Providence Medical Foundation (site 209)
-
Hoofdonderzoeker:
- Ian C Anderson, MD
-
Contact:
- Melissa Ulrich
- Telefoonnummer: 707-521-3833
- E-mail: melissa.ulrich@providence.org
-
Contact:
- Sam Hansen
- Telefoonnummer: 707-521-3829
- E-mail: samantha.hansen@stjoe.org
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06102
- Werving
- Hartford Hospital (site 210)
-
Contact:
- Hayley Yackel
- Telefoonnummer: 860-972-5518
- E-mail: hayley.dunnack@hhchealth.org
-
Hoofdonderzoeker:
- Jaykumar Thumar, MD
-
Contact:
- Holly Maheu
- Telefoonnummer: 1-860-972-5025
- E-mail: holly.maheu@hhchealth.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20037
- Werving
- The George Washington University Cancer Center (site 212)
-
Contact:
- Bethel Sebsebie, MS, BS
- Telefoonnummer: 202-994-1747
- E-mail: Bethel.sebsebie@gwu.edu
-
Hoofdonderzoeker:
- Pavani Chalasani, MD, MPH
-
Contact:
- Abby Lucas
- Telefoonnummer: 1-202-994-3647
- E-mail: allucas@gwu.edu
-
-
Florida
-
Fort Lauderdale, Florida, Verenigde Staten, 33308
- Werving
- Holy Cross Hospital (site 213)
-
Contact:
- Eileen Georgi
- Telefoonnummer: 954-542-7748
- E-mail: eileen.georgi@holy-cross.com
-
Contact:
- Denise Pichardo
- Telefoonnummer: 954-542-8565
- E-mail: denise.pichardo@holy-cross.com
-
Hoofdonderzoeker:
- Georges Azzi, MD
-
Pembroke Pines, Florida, Verenigde Staten, 33028
- Werving
- Memorial Cancer Institute at Memorial Healthcare Systems (site 132)
-
Hoofdonderzoeker:
- Luis E Raez, MD
-
Contact:
- Jorge Gonzalez Rivas
- Telefoonnummer: 954-265-2619
- E-mail: JGonzalezRivas@mhs.net
-
Contact:
- Ines Padron Cubillan, RN, BSN
- Telefoonnummer: 954-844-8737
- E-mail: IPadronCubillan@mhs.net
-
-
New Jersey
-
Englewood, New Jersey, Verenigde Staten, 07631
- Werving
- Englewood Hospital and Medical Center (site 202)
-
Contact:
- Dara Herman
- E-mail: Dara.Herman@EHMCHealth.org
-
Hoofdonderzoeker:
- Minaxi Jhawer, MD
-
Contact:
- Kayla Williams
- Telefoonnummer: 9786 201-894-3000
- E-mail: Kayla.Williams@EHMCHealth.org
-
Florham Park, New Jersey, Verenigde Staten, 07932
- Werving
- Summit Medical Group (site 205)
-
Contact:
- Michelle Mackenzie, RN, OCN, CCRC
- Telefoonnummer: 1-973-436-1755
- E-mail: mmackenzie@summithealth.com
-
Hoofdonderzoeker:
- Steven Papish, MD, FACP
-
Morristown, New Jersey, Verenigde Staten, 07962
- Werving
- Atlantic Health System, Morristown Medical Center (site 124)
-
Hoofdonderzoeker:
- Angela Alistar, MD
-
Contact:
- Tracey Hilden, RN, BSN, OCN
- Telefoonnummer: 973-971-7889
- E-mail: Tracey.Hilden@atlantichealth.org
-
Contact:
- Salome Geene, BSN, RN
- Telefoonnummer: 973-971-6373
- E-mail: salome.geene@atlantichealth.org
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87110
- Werving
- Presbyterian Kaseman Hospital (site 208)
-
Contact:
- Matthew Widdows, CCRC
- Telefoonnummer: 505-559-6089
- E-mail: mwiddows2@phs.org
-
Hoofdonderzoeker:
- Ethan Binder, MD
-
Contact:
- Kristina Garcia
- Telefoonnummer: 505-253-1718
- E-mail: kgarcia70@phs.org
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Werving
- Weill Cornell Medicine, Cornell University (site 126)
-
Contact:
- Marvin Castellon
- Telefoonnummer: 646-962-6091
- E-mail: mac7087@med.cornell.edu
-
Contact:
- Agustina Whamond
- E-mail: agw4002@med.cornell.edu
-
Hoofdonderzoeker:
- Ashish Saxena, M.D., Ph.D.
-
-
Pennsylvania
-
York, Pennsylvania, Verenigde Staten, 17403
- Werving
- Cancer Care Associates of York (site 206)
-
Hoofdonderzoeker:
- Chanh Huynh, MD
-
Contact:
- Katelyn Bean
- Telefoonnummer: 717-741-9229
- E-mail: kbean@wellspan.org
-
Contact:
- Jennifer Stough
- Telefoonnummer: 1-717-741-9229
- E-mail: jstough4@wellspan.org
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- The University of Texas MD Anderson Cancer Center (site 127)
-
Hoofdonderzoeker:
- David S Hong, MD
-
Contact:
- Ly M Nguyen
- Telefoonnummer: 713-563-2169
- E-mail: LMNguyen1@mdanderson.org
-
Contact:
- Madison Maas
- E-mail: MEMaas@mdanderson.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
#. Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma:
Phase 1 Dose Escalation only: Subjects with
(A) any advanced solid tumors of
- Head and Neck Cancers ("HNC") (of any types),
- Esophageal cancer,
- Lung cancers (of any types),
- Mesothelioma,
- Pancreatic cancers,
Or,
(B) any NTRK1 gene fusion positive ("NTRK1+") solid tumors or lymphomas, that is relapsed, refractory or intolerant (R/R/I) to standard of care (SOC) and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible.
Phase 2 Monotherapy and Combination with Pembrolizumab only:
Subjects must have
- TrkA-driven HNC, Esophageal, Lung, Mesothelioma, Pancreatic cancers; or,
- any NTRK1+ solid tumors or lymphoma*, that is R/R/I to SOC.
Key Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 or 1.
-
Able to swallow and retain oral medication.
-
Subjects must either have available archival tumor tissue samples, or consent to tumor tissue sampling prior to the first dose.
-
Adequate organ system function as defined as follows:
- Absolute neutrophil count ≥1.5x10^9/L
- Hemoglobin ≥9g/dL
- Platelets ≥100x10^9/L
- PT/INR, PTT ≤1.5xULN
- Total bilirubin ≤1.5x ULN
- AST, ALT ≤2.5xULN
- Creatinine ≤1.2xULN for age, weight
- Calculated creatinine clearance or 24h urine creatinine clearance ≥60mL/min
Key Exclusion Criteria:
-
Received chemotherapy having delayed toxicity within the last 14 days (six weeks for prior nitrosourea or mitomycin C).
-
Received anticancer therapy with radiation, immunotherapy, and a biologic, surgery and/or tumor embolization within the past 2 weeks.
-
Received an investigational anticancer drug within 14 days or 5 half-lives of the investigational agent, whichever is longer, prior to the first dose of VMD-928. Any exceptions to the above must be approved by the Sponsor Medical Monitor.
-
Unresolved toxicity from previous anticancer therapy > CTCAE Grade 1 (except alopecia or anemia) unless agreed to by both the Sponsor Medical Monitor and the Investigator.
-
Known active infections including HIV disease.
-
Currently pregnant, nursing, or planning to become pregnant during the course of the study.
-
QTcF interval ≥ 480 msec.
-
Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
-
Acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.
-
Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the patient's safety or interfere with assessment of the drug.
-
Psychological, familial, sociological, geographical, or other concurrent conditions that would interfere with safety evaluation, limit the patient's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Patients with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded.
-
Patient has had or is currently having other malignant tumors within 3 years.
-
Patients have multiple factors that affect their oral medication.
-
Patients have long-term unhealed wounds or fractures.
-
Patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage.
-
Patients are taking the following drugs and can't stop them during the study:
- Tylenol or medicine containing acetaminophen (paracetamol).
- Antacids (e.g. TUMS, calcium carbonate, or magnesium hydroxide), proton pump inhibitors (e.g. omeprazole), H2 blockers (e.g. famotidine), or buffered vitamins.
-
Epstein-Barr virus (EBV) negative nasopharyngeal carcinoma.
For Phase 2 only:
- Negative result on TrkA immunohistochemistry (IHC) assay.
- Have visceral crisis, defined as severe organ dysfunction and rapid progression of the cancer. (It is not about presence of visceral metastasis.)
For combination therapy with Pembrolizumab only:
- Serious adverse immune related adverse events (grade 3 or 4) with previous PD-1(L1) inhibitor therapy, that were symptomatic and required prolong immunosuppression (>6 weeks).
- Any grade Pneumonitis and Myocarditis related to prior PD-1(L1) inhibitor therapy.
- For subjects that received PD-1(L1) inhibitors before, there should be a washout period of at least 21 days between the last day of PD-1(L1) inhibitor and first day of study medications.
- Subjects who relapsed after prior treatment with PD-1(L1) inhibitors. Relapsed is defined as patients having best overall response of CR or PR after treatment with a PD-1(L1) inhibitor.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: VMD-928 monotherapy
VMD-928 tablet monotherapy |
Taken orally once daily for 21 days per 21-day cycle
Andere namen:
|
|
Experimenteel: Combination Therapy
VMD-928 tablet in combination with fixed dose of pembrolizumab 200 mg once-very-21-day (per cycle) |
VMD-928 tablet (oral) starting at 300 mg daily for 21 days of 21-day cycle. Pemprolizumab at fixed intravenous dose of 200 mg once-every-21 days (per cycle) for max. 6 cycles.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number and severity of treatment-emergent Adverse Events (Phase 1)
Tijdsspanne: First cycle (21 days per cycle)
|
TEAE |
First cycle (21 days per cycle)
|
|
To determine the recommended Phase 2 dose for VMD-928 (Phase 1)
Tijdsspanne: First cycle (21 days per cycle)
|
RP2D of monotherapy |
First cycle (21 days per cycle)
|
|
To determine the RP2D of VMD-928 in combination with pembrolizumab (Phase 1)
Tijdsspanne: First cycle (21 days per cycle)
|
RP2D of combination therapy |
First cycle (21 days per cycle)
|
|
Antitumor activity of VMD-928 in subjects with TrkA-driven tumors (Phase 2)
Tijdsspanne: Up to 18 months
|
Antitumor efficacy signal for monotherapy |
Up to 18 months
|
|
Antitumor activity of VMD-928 in combination with pembrolizumab in subjects with TrkA-driven tumors (Phase 2)
Tijdsspanne: Up to 18 months
|
Antitumor efficacy signal for combination therapy |
Up to 18 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Area under the plasma concentration versus time curve (AUC) of VMD-928.
Tijdsspanne: On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)
|
AUC |
On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)
|
|
Peak plasma concentration (Cmax) of VMD-928.
Tijdsspanne: On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)
|
Cmax |
On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)
|
|
Incidence of Dose Limiting Toxicities.
Tijdsspanne: During the Cycle 1 (each cycle is 21 days)
|
# of DLTs |
During the Cycle 1 (each cycle is 21 days)
|
|
Correlation between clinical antitumor and TrkA protein expression.
Tijdsspanne: Up to the end of the Cycle 2 (each cycle is 21 days)
|
Relationship of TrkA vs. efficacy |
Up to the end of the Cycle 2 (each cycle is 21 days)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Clinical Development, VM Oncology
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Longkanker
- NSCLC
- Niet-kleincellige longkanker
- HNSCC
- Adenoïd cystisch carcinoom
- Strottenhoofd
- Mesothelioom
- Hoofd- en nekkanker
- SCLC
- Pancreas
- HNC
- ACC
- Hypofarynx
- Slokdarm
- Luchtpijp
- Mondholte
- Orofarynx
- TrkA
- NTRK1
- Progressie na anti-PD-1/PD-L1-immunotherapie
- Amandelen
- Keel
- Nasofaryngeaal
- Hoofd-halscarcinoom
- Gevorderd na een immunotherapie
- Speekselkliercarcinoom
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Mondziekten
- Stomatognatische ziekten
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Longziekten
- Endocriene klierneoplasmata
- Alvleesklier Ziekten
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Neoplastische processen
- Slokdarmaandoeningen
- Adenoom
- Neoplasmata, mesotheliaal
- Carcinoom
- KNO-ziekten
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Speekselklierziekten
- Carcinoom, plaveiselcel
- Mond neoplasmata
- Pathologische aandoeningen, tekenen en symptomen
- Plaveiselcelcarcinoom van hoofd en hals
- Longneoplasmata
- Slokdarmneoplasmata
- Mesothelioom
- Neoplasma metastase
- Pancreasneoplasmata
- Carcinoom, niet-kleincellige long
- Hoofd- en nekneoplasmata
- Kleincellig longcarcinoom
- Carcinoom, adenoïde cystic
- Speekselklierneoplasmata
- Tracheale aandoeningen
- Laryngeale ziekten
- Farmaceutische voorbereidingen
- Therapeutica
- Doseringsvormen
- Gecombineerde modaliteitstherapie
- pembrolizumab
- Tabletten
Andere studie-ID-nummers
- VMO-01C
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .